Unraveling trajectories from aplastic anemia to hematologic malignancies: genetic and molecular insights
ConclusionThis study highlights the genetic dynamics in the progression from AA to hematologic malignancy. Monosomy 7’s prevalence and the occurrence of PTPN11 mutations suggest predictive and prognostic significance. Clonal evolution underscores the complexity of disease progression. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - March 13, 2024 Category: Cancer & Oncology Source Type: research
Dioscin alleviates aplastic anemia through regulatory T cells promotion
Conclusion: Dioscin markedly attenuated bone marrow failure, and promoted Tregs differentiation, suggesting the maintenance of theimmune balance effect of Dioscin. Dioscin attenuates pancytopenia and bone marrow failure via its Tregs promotion properties.PMID:38466633 | DOI:10.1080/16078454.2024.2326389 (Source: Hematology)
Source: Hematology - March 11, 2024 Category: Hematology Authors: Liwei Fan Runfeng Ni Haijin Wang Le Zhang Aidi Wang Baoshan Liu Source Type: research
HERVs may perform as the initial trigger for acquired aplastic anemia
J Transl Med. 2024 Mar 9;22(1):260. doi: 10.1186/s12967-024-05052-7.NO ABSTRACTPMID:38461345 | DOI:10.1186/s12967-024-05052-7 (Source: Cancer Control)
Source: Cancer Control - March 9, 2024 Category: Cancer & Oncology Authors: Ting Wang Nianbin Li Heng Wu Rong Fu Source Type: research
Unrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia
Blood Cancer Journal, Published online: 06 March 2024; doi:10.1038/s41408-024-01021-xUnrelated donor hematopoietic stem cell transplantation compared to immunosuppressive therapy plus eltrombopag as first-line treatment for adults with severe aplastic anemia (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 6, 2024 Category: Hematology Authors: Liangliang Wu Limin Liu Xin Zhao Ming Zhou Andie Fu Yuping Zhang Wenrui Yang Xiaowei Chen Wenjian Mo Caixia Wang Yumiao Li Shilin Xu Shiyi Pan Ruiqing Zhou Fankai Meng Fengkui Zhang Depei Wu Shunqing Wang Source Type: research
Co-transplantation of umbilical cord mesenchymal stem cells and peripheral blood stem cells in children and adolescents with refractory or relapsed severe aplastic anemia
. (Source: Pediatric Hematology and Oncology)
Source: Pediatric Hematology and Oncology - March 4, 2024 Category: Pediatrics Authors: Fangfang YuanMinghui LiXudong WeiYuewen FuThe Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan, China Source Type: research
Recombinant Human Thrombopoietin Promotes Platelet Engraftment in Severe Aplastic Anemia Patients following Treatment with Haploid Hematopoietic Stem Cell Transplantation using Modified Post-transplantation Cyclophosphamide
Severe aplastic anemia (SAA) is a life-threatening disorder characterized by peripheral blood pancytopenia resulting from bone marrow failure1, 2. Intensive immunosuppressive therapy (IST) and human leukocyte antigen (HLA)-matched sibling donor-hematopoietic stem cell transplantation (MSD-HSCT) are the standard treatment options for SAA. Due to the slow hematopoietic recovery of IST and limited donor sources for MSD-HSCT, HLA-haploidentical-hematopoietic stem cell transplantation (Haplo-HSCT) has become an effective alternative therapy3-5. (Source: Biology of Blood and Marrow Transplantation)
Source: Biology of Blood and Marrow Transplantation - March 3, 2024 Category: Hematology Authors: Andie Fu, Yizhou Peng, Ping Cheng, Jiaying Wu, Xiaojian Zhu, Yang Yang, Lifang Huang, Na Wang, Jue Wang, Jinhuan Xu, Yuling Wan, Yang Cao, Jia Wei, Yi Xiao, Fankai Meng, Hui Cheng, Yicheng Zhang, Donghua Zhang Source Type: research
Clinical signs and treatment of New-onset Bone marrow failure associated SARS-CoV-2 infection in Children : a single institution prospective cohort study .
Conclusion: SARS-CoV-2 virus is added to several viral infections known to be implicated in the pathogenesis of aplastic anaemia. Studies are needed to establish a definitive association and determine whether the response of bone marrow failure to standard therapy differ from that of idiopathic cases. (Source: Mediterranean Journal of Hematology and Infectious Diseases)
Source: Mediterranean Journal of Hematology and Infectious Diseases - February 29, 2024 Category: Hematology Authors: Mervat A M youssef, Ebtisam Shawky hmed, Dalia Tarik Kamal, khalid Elsayh,, Mai A Abdelfatta, Hyam Hassan Mahran Mahran, Mostafa M Embaby Source Type: research
Progress in medical therapy in aplastic anemia: why it took so long?
Int J Hematol. 2024 Feb 26. doi: 10.1007/s12185-024-03713-3. Online ahead of print.ABSTRACTThe treatment of aplastic anemia (AA) has significantly advanced in the last 50 years, evolving from a fatal condition to one where survival rates now exceed 80-85%. Hematopoietic stem cell transplantation (HSCT) and immunosuppressive therapy (IST) have become the primary treatments, with the latter widely adopted due to factors like the scarcity of compatible donors, patient age, comorbidities, and limited HSCT access. A therapy breakthrough was the introduction of antithymocyte globulin (ATG), with its effectiveness further boosted...
Source: International Journal of Hematology - February 25, 2024 Category: Hematology Authors: Phillip Scheinberg Source Type: research
Aplastic anemia secondary to adjuvant Osimertinib therapy: a case report and a review of literature
We present a case report of a 63-year-old patient with locally advanced non-small cell lung cancer (NSCLC) who developed aplastic anemia following adjuvant treatment with Osimertinib. Extensive investigations ruled out infectious etiology, and the absence of bone marrow involvement or other identifiable causes suggested a drug-induced etiology, specifically Osimertinib. This case report emphasizes the importance of recognizing this adverse event and considering it as a potential complication of Osimertinib therapy. Vigilant monitoring and prompt management are essential for optimizing patient outcomes. Further studies are ...
Source: Frontiers in Oncology - February 22, 2024 Category: Cancer & Oncology Source Type: research
